Summary & Overview
HCPCS C9358: Dermal Substitute, Fetal Bovine Collagen (Surgimend)
HCPCS Level II code C9358 identifies a native, non-denatured fetal bovine collagen dermal substitute (Surgimend collagen matrix) billed per 0.5 square centimeters. The code captures use of a biologic dermal graft in soft-tissue reconstruction and wound repair, which is clinically significant as biologic matrices are increasingly used to support healing in complex surgical and reconstructive procedures. Nationally, use of dermal substitutes affects outpatient surgical resource utilization and specialty supply management.
Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what C9358 represents, the typical clinical settings for its application, and the payer landscape addressed. The publication provides benchmarks where available, summaries of relevant coverage patterns and coding considerations, and clinical context regarding the service line. Data not available in the input will be noted as such. This summary is intended to help billing professionals, clinical administrators, and policy analysts understand the coding designation and its role in surgical supply reporting and reimbursement workflows.
Billing Code Overview
HCPCS Level II code C9358 describes a dermal substitute composed of native, non-denatured collagen of fetal bovine origin (Surgimend collagen matrix), billed per 0.5 square centimeters. This product is a biologic graft material used to support soft-tissue repair and reconstruction.
Service Type: Dermal substitute / biologic graft application
Typical Site of Service: Outpatient surgical settings such as ambulatory surgery centers or hospital outpatient departments where soft-tissue reconstruction or wound repair procedures are performed.
Clinical & Coding Specifications
Clinical Context
A patient with a full-thickness soft tissue defect following surgical excision of a skin cancer or traumatic wound presents for reconstruction using a dermal substitute. The procedure uses a native, non-denatured fetal bovine collagen matrix (C9358) applied to the wound bed to support dermal regeneration and provide a biologic scaffold prior to definitive closure or secondary intention healing. Typical workflow: preoperative assessment and wound bed preparation (debridement and hemostasis) in an outpatient minor procedure room, ambulatory surgery center, or inpatient operating room; measurement of the defect to determine required matrix area; application and securement of the C9358 collagen matrix to the wound, often covered with a non-adherent dressing or negative pressure wound therapy; postoperative dressing changes and monitoring for graft take and infection. Typical sites of service include ambulatory surgery centers, hospital outpatient departments, and wound care specialty clinics. Patient factors commonly include postoperative or post-excisional soft tissue defects, chronic non-healing ulcers converted to a prepared recipient site, or traumatic soft tissue loss where a collagen dermal matrix is indicated to facilitate regeneration before definitive closure or skin grafting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |